.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.The Eli Lilly-partnered biotech hopes to detail on the Nasdaq under the icon "BIOA," depending on to papers filed with the Stocks and Swap Percentage. The firm has not publicly shared an anticipated monetary quantity for the offering.The clinical-stage company promotes lead candidate azelaprag, a by mouth delivered small molecule slated to get into stage 2 testing in combination with semaglutide-- offered by Novo Nordisk under brand name Wegovy for fat loss-- in the initial one-half of next year. Semaglutide is also sold as Ozempic and Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is designed to combine properly with GLP-1 medicines, improving weight management while maintaining muscular tissue mass. The investigational medication was actually located to be well-tolerated among 265 people across 8 phase 1 tests, depending on to BioAge.Previously, BioAge got the help of Lilly to run a trial combining azelaprag along with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro and Zepbound for weight loss. The companions are actually presently administering a period 2 trial of azelaprag and also tirzepatide, along with topline outcomes anticipated in the 3rd quarter of 2025.The biotech is actually also organizing a blood insulin sensitiveness proof-of-concept trial analyzing azelaprag as a monotherapy in the initial half of upcoming year to assist possible indicator growth. Additionally, the firm prepares to ask the FDA for authorization in the second one-half of 2025 to introduce human testing for an NLRP3 prevention targeting metabolic diseases as well as neuroinflammation.BioAge's foreseed relocate to the public market follows a slight uptick in planned biotech IPOs coming from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the recent IPO garden is a "mixed picture," with top notch business still debuting on everyone markets, only in decreased numbers, according to PitchBook.